Electronic Resource
Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
| العنوان: | Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab. |
|---|---|
| المؤلفون: | Brown F., Choo S.Z. |
| بيانات النشر: | Blackwell Publishing (E-mail: info@asia.blackpublishing.com.au) Australia 2017-03-13 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | A 25-year-old man presented with microangiopathic haemolytic anaemia and acute kidney injury. With a normal ADAMTS-13 level, negative faecal shiga-toxin test and strong family history of atypical haemolytic uremic syndrome, he was commenced on eculizumab to good clinical response. Subsequent genetic testing revealed a heterozygous complement factor H mutation. Eculizumab was discontinued after 44 months of treatment, and he relapsed within 6 months, with the first sign being downtrending haptoglobin levels, with no other markers of haemolysis or thrombocytopaenia, 5 weeks prior to development of acute kidney injury. He was recommenced on eculizumab and to date still remains on it. This case highlights the unusual pattern of relapse and discusses the considerations for eculizumab discontinuation in patients with stable atypical haemolytic uremic syndrome receiving maintenance therapy.Copyright © 2017 Asian Pacific Society of Nephrology |
| مصطلحات الفهرس: | hemolytic uremic syndrome/th [Therapy], hemolytic uremic syndrome/dt [Drug Therapy], human, kidney biopsy, lethargy/co [Complication], maintenance therapy, male, malignant hypertension/co [Complication], malignant hypertension/dt [Drug Therapy], nausea/co [Complication], nonhuman, Norovirus, plasmapheresis, relapse, review, seizure/co [Complication], thrombocyte count, thrombocytopenia/di [Diagnosis], thrombotic thrombocytopenic purpura/di [Diagnosis], thrombotic thrombocytopenic purpura/th [Therapy], treatment duration, urea blood level, vomiting, complement factor H/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], eculizumab/dt [Drug Therapy], haptoglobin/ec [Endogenous Compound], hemoglobin/ec [Endogenous Compound], labetalol/dt [Drug Therapy], lactate dehydrogenase/ec [Endogenous Compound], lercanidipine/dt [Drug Therapy], ramipril/dt [Drug Therapy], von Willebrand factor cleaving proteinase/ec [Endogenous Compound], complement factor H gene, fecal shiga toxin test, helmet cell, acute kidney failure/di [Diagnosis], adult, case report, cells, diarrhea, erythrocyte, erythrocyte disorder, family history, feces analysis, gene mutation, genetic screening, headache/co [Complication], hematuria/di [Diagnosis], hemodialysis, hemolysis, Review |
| URL: | Nephrology Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2017 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/39530 Nephrology. 22 (Supplement 1) (pp 4-6), 2017. Date of Publication: 01 Feb 2017. 1320-5358 https://repository.monashhealth.org/monashhealthjspui/handle/1/39530 Nephrology 28176471 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28176471] 614367209 (Choo, Brown) Department of Nephrology, Monash Health, Australia Choo S.Z.; chooshizhou@hotmail.com (Choo, Brown) Department of Nephrology, Monash Health, Australia 1305109597 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305109597 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |